The HLA-B*5101 Molecule-Binding Capacity to Antigens Used in Animal Models of Behcet's Disease: A Bioinformatics Study

作者：Baharav Ehud^*; Weinberger Abraham

来源：Israel Medical Association Journal, 2012, 14(7): 424-428.

• Behcet's disease (BD)
• autoantigens
• animal models
• HLA-B*5101

Background: The human lymphocyte antigen (HLA) molecule B*5101 is a functioning receptor of the immune system and is generally accepted as a genetic marker for Behcet disease (BD), a multi-organ, chronic inflammatory disorder. The role of the HLA-B*5101 in the pathogenesis of BD is elusive. The assumption that HLA-B*5101 has an active role in BD is suggestive, but no antigen has yet been identified.
Objectives: To evaluate the potential binding capacity of various antigens to the HLA-B*5101 molecule.
Methods: Using bioinformatics programs, we studied the binding capacity of HLA-B*5101 and its corresponding rat molecule RT.A1 to the following antigens: heat shock protein-60 (HSP60), major histocompatibility complex class I chain-related gene A (MICA), retinal S-antigen (S-Ag), HLA-B27 molecule and its peptide (PD) and tropomyosin (TPM), all of which serve as antigens in animal models corresponding to BD.
Results: In each protein including the B*5101 molecule itself, the computerized programs revealed several short sequences with potential high binding capacity to HLA-B*5101 with the exception of B-27PD. The rat MHC RT1. Al. had no binding capacity to S-Ag.
Conclusions: The evaluated proteins have the potential to bind to and to serve as potential antigens to the HLA-B*5101 and the rat MHC RT1.Al. molecules. The pathogenicity of these suggested short peptides should be evaluated in animal models of BD. IMAJ 2012; 14: 424-428

• 出版日期2012-7